Research Analysts’ Weekly Ratings Changes for Denali Therapeutics (DNLI)

Several brokerages have updated their recommendations and price targets on shares of Denali Therapeutics (NASDAQ: DNLI) in the last few weeks:

• 11/4/2026 – Denali Therapeutics had its price target raised by Morgan Stanley from $40.00 to $42.00. They now have an “overweight” rating on the stock.
• 11/4/2026 – Denali Therapeutics had its price target raised by Wedbush from $23.00 to $24.00. They now have an “outperform” rating on the stock.
• 11/4/2026 – Denali Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.
• 10/24/2026 – Denali Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 10/15/2026 – Denali Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/10/2026 – Denali Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 9/19/2026 – Denali Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.

Denali Therapeutics Trading Down 5.9%

Denali Therapeutics stock traded down $1.24 during trading hours on Thursday, reaching $19.72. The company had a trading volume of 2,249,461 shares, compared to its average volume of 1,739,193. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. Denali Therapeutics Inc. has a 12-month low of $13.75 and a 12-month high of $27.30. The company has a 50-day moving average price of $20.35 and a 200 day moving average price of $21.25. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of -11.40 and a beta of 1.08.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings data on Tuesday, November 3rd. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.64. The company had revenue of $17.78 million for the quarter, compared to analysts’ expectations of $12.67 million. During the same period last year, the company posted ($0.74) EPS. Equities analysts forecast that Denali Therapeutics Inc. will post -2.70 earnings per share for the current year.

Insider Activity at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 2,857 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total transaction of $71,624.99. Following the completion of the transaction, the insider directly owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 9.70% of the company’s stock.

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.